Eastwood Bio-Medical Canada Inc. (EWOOF)
- Previous Close
0.6937 - Open
0.5793 - Bid --
- Ask --
- Day's Range
0.6937 - 0.6937 - 52 Week Range
0.5793 - 1.2000 - Volume
31,000 - Avg. Volume
0 - Market Cap (intraday)
47.786M - Beta (5Y Monthly) 0.56
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date Apr 29, 2024 - Apr 30, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Eastwood Bio-Medical Canada Inc. markets and distributes natural health products under the Eleotin brand in Canada, the United States, and Asia. It distributes Eleotin that provide natural remedies for metabolic disorders, such as blood glucose disorders, hypertension, and obesity. The company's licensed products include Eleotin A 700 for the treatment for spleen deficiency, lack of appetite, and fatigue; Eleotin AL88 for laxative; Eleotin Cal20 for bone and teeth maintenance; Eleotin V3D for development and maintenance of bones, teeth, and good health; Eleotin G2000 for cardiovascular health; Eleotin H55 for sedative and tension relief; and Eleotin Zn330 for tissue formation and metabolism. Its products also include Eleotin Bentley to promote healthy glucose levels; and Eleotin LBM for hypertension relief. The company was incorporated in 2010 and is based in Richmond, Canada. Eastwood Bio-Medical Canada Inc. operates as a subsidiary of Eastwood Bio-Medical Research Inc.
www.eleotin.ca--
Full Time Employees
October 31
Fiscal Year Ends
Sector
Industry
Recent News: EWOOF
Performance Overview: EWOOF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: EWOOF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: EWOOF
Valuation Measures
Market Cap
44.22M
Enterprise Value
44.25M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
57.34
Price/Book (mrq)
--
Enterprise Value/Revenue
60.06
Enterprise Value/EBITDA
-108.30
Financial Highlights
Profitability and Income Statement
Profit Margin
-72.15%
Return on Assets (ttm)
-64.96%
Return on Equity (ttm)
--
Revenue (ttm)
736.75k
Net Income Avi to Common (ttm)
-531.6k
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
6.02k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
180.07k
Company Insights: EWOOF
EWOOF does not have Company Insights